Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of
nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).